POTSDAM, GERMANY--(Marketwire - October 26, 2010) - Signature Diagnostics AG announced today
that the company was selected to present its newest blood-based products
for
colorectal cancer (CRC) screening -- Detector C and Detector C/Plus -- at
the
18th United European Gastrointestinal Week (UEGW) Congress in Barcelona on
October 22-26, 2010. The paper, "Early Detection of Colorectal Cancer Based
on
RNA Measurements in Blood," will be presented by the company's CEO, André
Rosenthal, Ph.D, at the session "Colorectal Cancer Screening: New
Strategies" on
Wednesday, October 26, 2010 (Hall 14, 8:30-10:30am).
Both Detector C and Detector C/Plus are extremely accurate and safe with a
validated sensitivity of 90 percent and a validated specificity of up to
92.5
percent. Both tests should be applicable to individuals who dislike
colonoscopy
due to bowel cleaning and its invasiveness, dislike stool-based tests, or
are
above 70-years-old and may have conditions that increase the risks of
colonoscopy and side effects.
"The use of Detector C and Detector C/Plus as primary screening tools not
only
increases sensitivity and specificity of blood-based CRC screening, but
would
result in significantly fewer unnecessary colonoscopies in countries where
screening colonoscopy is reimbursed," said André Rosenthal. "The test's low
false positive rate of 7.5 percent is close to that of colonoscopy and
ensures
that endoscopy resources will not be exhausted by large-scale use of this
blood-based test."
About Signature Diagnostics AG
Signature Diagnostics AG is a molecular diagnostics company based in
Potsdam,
Germany, focusing on the development and commercialization of novel
molecular
oncology diagnostic products for early detection (screening) and prognosis
of
cancer. The company has completed development of its first two diagnostic
products for colorectal cancer screening ("Detector C/C+") and prognosis
("Predictor C"), which will be launched in early 2011 in its own ISO 15189
certified service laboratory. Using its state-of-the-art technologies in
tissue
and blood sample collection, molecular pathology, Xenopatient™ platform,
genome-wide profiling, data mining, and biostatistics, the company
collaborates
with clinical, pharmaceutical, and diagnostic partners. Signature
Diagnostics
sponsors and conducts large prospective, multicenter clinical trials with
more
than 25 primary care hospitals and several dozen colonoscopy centers in
Germany
to discover and validate biomarkers in oncology.
Signature Diagnostics
Hermannswerder 20 A Potsdam Germany
Press release (PDF):
http://hugin.info/143237/R/1455579/395446.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
